布林佐胺治疗青光眼的降眼压疗效及安全性观察

Effect and Safety Observation Brinzolamide in Lowering Intraocular Pressure of Glaucoma

目的探讨布林佐胺治疗青光眼的降眼压疗效及安全性。方法选取2014年8月至2016年10月期间本院收治的青光眼合并高眼压症的74例患者作为研究对象,随机分为对照组和观察组,各37例。观察组采用布林佐胺滴眼液治疗,对照组采用马来酸噻吗洛尔滴眼液治疗,观察两组患者治疗前和治疗2周、4周、6周、8周后眼压改变情况,同时观察两组不良反应发生情况。结果治疗2周后,观察组眼压(22.69±2.25)mm Hg略低于对照组(23.36±2.02)mm Hg,但无统计学差异P>0.05。观察组治疗4周(19.35±1.89)mm Hg、治疗6周(17.78±1.79)mm Hg、治疗8周(16.93±2.36)mm Hg、治疗12周(16.09±1.82)mm Hg后眼压水平均显著低于对照组(22.06±1.96)mm Hg、(21.34±2.03)mm Hg、(20.68±0.24)mm Hg、(19.25±2.04)mm Hg,组间差异P<0.05。观察组滴眼治疗期间不良反应发生率为8.11%(3/37),显著低于对照组18.92%,(7/37),组间差异P<0.05。结论青光眼患者采用布林佐胺滴眼液治疗,可有效降低患者眼压,且不良反应风险较低,临床应用安全可靠。

Objective To investigate lowering intraocular pressure effect and safety of brinzolamide for glaucoma brindza. Methods Choose 74 cases glaucoma and intraocular hypertension patients admitted in our hospital from August 2014 to October 2016, divide them into control and observation group randomly, 37 cases in each. Observation group was treated with brinzolamide eye drops, and control group with timolol maleate eye drops. Observe intraocular pressure changes of two groups before treatment and 2, 4, 6 and 8 weeks after treatment, at the same time, observe incidence of adverse reactions of two groups. Results 2 weeks after treatment, IOP of observation group(22.69±2.25) mm Hg was slightly lower than control group(23.36±2.02) mm Hg, there was no statistical difference, P>0.05. In observation group, 4 weeks after treatment IOP was(19.35±1.89) mm Hg, 6 weeks after treatment(17.78±1.79) mm Hg, 8 weeks after treatment(16.93±2.36) mm Hg, 12 weeks after treatment(16.09±1.82) mm Hg, was significantly lower than control group,(22.06±1.96), mm Hg(21.34±2.03) mm Hg,(20.68±0.24), mm Hg(19.25±2.04) mm Hg, difference between groups showed P<0.05. Incidence of adverse reactions of observation group during eye drop treatment was 8.11%(3/37), significantly lower than control group 18.92%(7/37), difference between groups showed P<0.05. Conclusion Brinzolamide eye drops can reduce intraocular pressure of treatment of glaucoma patients effectively, with low risks of adverse reactions, which is safe and reliable in clinical application.